

Global Mucopolysaccharidosis Treatment Market Research Report 2023

<https://marketpublishers.com/r/G3D55902CF86EN.html>

Date: December 2023

Pages: 94

Price: US\$ 2,900.00 (Single User License)

ID: G3D55902CF86EN

Abstracts

MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).

According to QYResearch's new survey, global Mucopolysaccharidosis Treatment market is projected to reach US\$ 3392.8 million in 2029, increasing from US\$ 2381 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mucopolysaccharidosis Treatment market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mucopolysaccharidosis Treatment market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Shire (Takeda Pharmaceutical Company Limited)

Denali Therapeutics

ArmaGen

REGENXBIO Inc.

Sangamo Therapeutics

BioMarin

Lysogene

Abeona Therapeutics Inc.

Ultragenyx Pharmaceutical

Genzyme Corporation

Segment by Type

Intravenous

Intracerebroventricular (ICV)

Segment by Application

Hospital

Clinic

Other

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Mucopolysaccharidosis Treatment report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Mucopolysaccharidosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Intravenous

1.2.3 Intracerebroventricular (ICV)

1.3 Market by Application

1.3.1 Global Mucopolysaccharidosis Treatment Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Mucopolysaccharidosis Treatment Market Perspective (2018-2029)

2.2 Mucopolysaccharidosis Treatment Growth Trends by Region

2.2.1 Global Mucopolysaccharidosis Treatment Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Mucopolysaccharidosis Treatment Historic Market Size by Region (2018-2023)

2.2.3 Mucopolysaccharidosis Treatment Forecasted Market Size by Region (2024-2029)

2.3 Mucopolysaccharidosis Treatment Market Dynamics

2.3.1 Mucopolysaccharidosis Treatment Industry Trends

2.3.2 Mucopolysaccharidosis Treatment Market Drivers

2.3.3 Mucopolysaccharidosis Treatment Market Challenges

2.3.4 Mucopolysaccharidosis Treatment Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Mucopolysaccharidosis Treatment Players by Revenue

3.1.1 Global Top Mucopolysaccharidosis Treatment Players by Revenue (2018-2023)

- 3.1.2 Global Mucopolysaccharidosis Treatment Revenue Market Share by Players (2018-2023)
- 3.2 Global Mucopolysaccharidosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Mucopolysaccharidosis Treatment Revenue
- 3.4 Global Mucopolysaccharidosis Treatment Market Concentration Ratio
 - 3.4.1 Global Mucopolysaccharidosis Treatment Market Concentration Ratio (CR5 and HHI)
 - 3.4.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis Treatment Revenue in 2022
- 3.5 Mucopolysaccharidosis Treatment Key Players Head office and Area Served
- 3.6 Key Players Mucopolysaccharidosis Treatment Product Solution and Service
- 3.7 Date of Enter into Mucopolysaccharidosis Treatment Market
- 3.8 Mergers & Acquisitions, Expansion Plans

4 MUCOPOLYSACCHARIDOSIS TREATMENT BREAKDOWN DATA BY TYPE

- 4.1 Global Mucopolysaccharidosis Treatment Historic Market Size by Type (2018-2023)
- 4.2 Global Mucopolysaccharidosis Treatment Forecasted Market Size by Type (2024-2029)

5 MUCOPOLYSACCHARIDOSIS TREATMENT BREAKDOWN DATA BY APPLICATION

- 5.1 Global Mucopolysaccharidosis Treatment Historic Market Size by Application (2018-2023)
- 5.2 Global Mucopolysaccharidosis Treatment Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America Mucopolysaccharidosis Treatment Market Size (2018-2029)
- 6.2 North America Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 6.3 North America Mucopolysaccharidosis Treatment Market Size by Country (2018-2023)
- 6.4 North America Mucopolysaccharidosis Treatment Market Size by Country (2024-2029)
- 6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Mucopolysaccharidosis Treatment Market Size (2018-2029)

7.2 Europe Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Mucopolysaccharidosis Treatment Market Size by Country (2018-2023)

7.4 Europe Mucopolysaccharidosis Treatment Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Mucopolysaccharidosis Treatment Market Size (2018-2029)

8.2 Asia-Pacific Mucopolysaccharidosis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2018-2023)

8.4 Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Mucopolysaccharidosis Treatment Market Size (2018-2029)

9.2 Latin America Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Mucopolysaccharidosis Treatment Market Size by Country (2018-2023)

9.4 Latin America Mucopolysaccharidosis Treatment Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Mucopolysaccharidosis Treatment Market Size (2018-2029)

10.2 Middle East & Africa Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2018-2023)

10.4 Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Shire (Takeda Pharmaceutical Company Limited)

11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Detail

11.1.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview

11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Treatment Introduction

11.1.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.1.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development

11.2 Denali Therapeutics

11.2.1 Denali Therapeutics Company Detail

11.2.2 Denali Therapeutics Business Overview

11.2.3 Denali Therapeutics Mucopolysaccharidosis Treatment Introduction

11.2.4 Denali Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.2.5 Denali Therapeutics Recent Development

11.3 ArmaGen

11.3.1 ArmaGen Company Detail

11.3.2 ArmaGen Business Overview

11.3.3 ArmaGen Mucopolysaccharidosis Treatment Introduction

11.3.4 ArmaGen Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.3.5 ArmaGen Recent Development

11.4 REGENXBIO Inc.

11.4.1 REGENXBIO Inc. Company Detail

11.4.2 REGENXBIO Inc. Business Overview

11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Treatment Introduction

11.4.4 REGENXBIO Inc. Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.4.5 REGENXBIO Inc. Recent Development

11.5 Sangamo Therapeutics

11.5.1 Sangamo Therapeutics Company Detail

11.5.2 Sangamo Therapeutics Business Overview

11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Treatment Introduction

11.5.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.5.5 Sangamo Therapeutics Recent Development

11.6 BioMarin

11.6.1 BioMarin Company Detail

11.6.2 BioMarin Business Overview

11.6.3 BioMarin Mucopolysaccharidosis Treatment Introduction

11.6.4 BioMarin Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.6.5 BioMarin Recent Development

11.7 Lysogene

11.7.1 Lysogene Company Detail

11.7.2 Lysogene Business Overview

11.7.3 Lysogene Mucopolysaccharidosis Treatment Introduction

11.7.4 Lysogene Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.7.5 Lysogene Recent Development

11.8 Abeona Therapeutics Inc.

11.8.1 Abeona Therapeutics Inc. Company Detail

11.8.2 Abeona Therapeutics Inc. Business Overview

11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Treatment Introduction

11.8.4 Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

11.8.5 Abeona Therapeutics Inc. Recent Development

11.9 Ultragenyx Pharmaceutical

11.9.1 Ultragenyx Pharmaceutical Company Detail

11.9.2 Ultragenyx Pharmaceutical Business Overview

11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Treatment Introduction

11.9.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)

- 11.9.5 Ultragenyx Pharmaceutical Recent Development
- 11.10 Genzyme Corporation
 - 11.10.1 Genzyme Corporation Company Detail
 - 11.10.2 Genzyme Corporation Business Overview
 - 11.10.3 Genzyme Corporation Mucopolysaccharidosis Treatment Introduction
 - 11.10.4 Genzyme Corporation Revenue in Mucopolysaccharidosis Treatment Business (2018-2023)
 - 11.10.5 Genzyme Corporation Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Mucopolysaccharidosis Treatment Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Intravenous

Table 3. Key Players of Intracerebroventricular (ICV)

Table 4. Global Mucopolysaccharidosis Treatment Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 5. Global Mucopolysaccharidosis Treatment Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Mucopolysaccharidosis Treatment Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Mucopolysaccharidosis Treatment Market Share by Region (2018-2023)

Table 8. Global Mucopolysaccharidosis Treatment Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Mucopolysaccharidosis Treatment Market Share by Region (2024-2029)

Table 10. Mucopolysaccharidosis Treatment Market Trends

Table 11. Mucopolysaccharidosis Treatment Market Drivers

Table 12. Mucopolysaccharidosis Treatment Market Challenges

Table 13. Mucopolysaccharidosis Treatment Market Restraints

Table 14. Global Mucopolysaccharidosis Treatment Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Mucopolysaccharidosis Treatment Market Share by Players (2018-2023)

Table 16. Global Top Mucopolysaccharidosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Treatment as of 2022)

Table 17. Ranking of Global Top Mucopolysaccharidosis Treatment Companies by Revenue (US\$ Million) in 2022

Table 18. Global 5 Largest Players Market Share by Mucopolysaccharidosis Treatment Revenue (CR5 and HHI) & (2018-2023)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Mucopolysaccharidosis Treatment Product Solution and Service

Table 21. Date of Enter into Mucopolysaccharidosis Treatment Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Mucopolysaccharidosis Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Mucopolysaccharidosis Treatment Revenue Market Share by Type (2018-2023)

Table 25. Global Mucopolysaccharidosis Treatment Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Mucopolysaccharidosis Treatment Revenue Market Share by Type (2024-2029)

Table 27. Global Mucopolysaccharidosis Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Mucopolysaccharidosis Treatment Revenue Market Share by Application (2018-2023)

Table 29. Global Mucopolysaccharidosis Treatment Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Mucopolysaccharidosis Treatment Revenue Market Share by Application (2024-2029)

Table 31. North America Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 32. North America Mucopolysaccharidosis Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 33. North America Mucopolysaccharidosis Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 34. Europe Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. Europe Mucopolysaccharidosis Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 36. Europe Mucopolysaccharidosis Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Asia-Pacific Mucopolysaccharidosis Treatment Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2018-2023) & (US\$ Million)

Table 39. Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2024-2029) & (US\$ Million)

Table 40. Latin America Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Latin America Mucopolysaccharidosis Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 42. Latin America Mucopolysaccharidosis Treatment Market Size by Country

(2024-2029) & (US\$ Million)

Table 43. Middle East & Africa Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 46. Shire (Takeda Pharmaceutical Company Limited) Company Detail

Table 47. Shire (Takeda Pharmaceutical Company Limited) Business Overview

Table 48. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Treatment Product

Table 49. Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 50. Shire (Takeda Pharmaceutical Company Limited) Recent Development

Table 51. Denali Therapeutics Company Detail

Table 52. Denali Therapeutics Business Overview

Table 53. Denali Therapeutics Mucopolysaccharidosis Treatment Product

Table 54. Denali Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 55. Denali Therapeutics Recent Development

Table 56. ArmaGen Company Detail

Table 57. ArmaGen Business Overview

Table 58. ArmaGen Mucopolysaccharidosis Treatment Product

Table 59. ArmaGen Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 60. ArmaGen Recent Development

Table 61. REGENXBIO Inc. Company Detail

Table 62. REGENXBIO Inc. Business Overview

Table 63. REGENXBIO Inc. Mucopolysaccharidosis Treatment Product

Table 64. REGENXBIO Inc. Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 65. REGENXBIO Inc. Recent Development

Table 66. Sangamo Therapeutics Company Detail

Table 67. Sangamo Therapeutics Business Overview

Table 68. Sangamo Therapeutics Mucopolysaccharidosis Treatment Product

Table 69. Sangamo Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 70. Sangamo Therapeutics Recent Development

Table 71. BioMarin Company Detail

Table 72. BioMarin Business Overview

Table 73. BioMarin Mucopolysaccharidosis Treatment Product

Table 74. BioMarin Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 75. BioMarin Recent Development

Table 76. Lysogene Company Detail

Table 77. Lysogene Business Overview

Table 78. Lysogene Mucopolysaccharidosis Treatment Product

Table 79. Lysogene Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 80. Lysogene Recent Development

Table 81. Abeona Therapeutics Inc. Company Detail

Table 82. Abeona Therapeutics Inc. Business Overview

Table 83. Abeona Therapeutics Inc. Mucopolysaccharidosis Treatment Product

Table 84. Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 85. Abeona Therapeutics Inc. Recent Development

Table 86. Ultragenyx Pharmaceutical Company Detail

Table 87. Ultragenyx Pharmaceutical Business Overview

Table 88. Ultragenyx Pharmaceutical Mucopolysaccharidosis Treatment Product

Table 89. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 90. Ultragenyx Pharmaceutical Recent Development

Table 91. Genzyme Corporation Company Detail

Table 92. Genzyme Corporation Business Overview

Table 93. Genzyme Corporation Mucopolysaccharidosis Treatment Product

Table 94. Genzyme Corporation Revenue in Mucopolysaccharidosis Treatment Business (2018-2023) & (US\$ Million)

Table 95. Genzyme Corporation Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Mucopolysaccharidosis Treatment Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Mucopolysaccharidosis Treatment Market Share by Type: 2022 VS 2029

Figure 3. Intravenous Features

Figure 4. Intracerebroventricular (ICV) Features

Figure 5. Global Mucopolysaccharidosis Treatment Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 6. Global Mucopolysaccharidosis Treatment Market Share by Application: 2022 VS 2029

Figure 7. Hospital Case Studies

Figure 8. Clinic Case Studies

Figure 9. Other Case Studies

Figure 10. Mucopolysaccharidosis Treatment Report Years Considered

Figure 11. Global Mucopolysaccharidosis Treatment Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 12. Global Mucopolysaccharidosis Treatment Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 13. Global Mucopolysaccharidosis Treatment Market Share by Region: 2022 VS 2029

Figure 14. Global Mucopolysaccharidosis Treatment Market Share by Players in 2022

Figure 15. Global Top Mucopolysaccharidosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Treatment as of 2022)

Figure 16. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis Treatment Revenue in 2022

Figure 17. North America Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 18. North America Mucopolysaccharidosis Treatment Market Share by Country (2018-2029)

Figure 19. United States Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. Canada Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. Europe Mucopolysaccharidosis Treatment Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 22. Europe Mucopolysaccharidosis Treatment Market Share by Country (2018-2029)

Figure 23. Germany Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. France Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. U.K. Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Italy Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Russia Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Nordic Countries Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Asia-Pacific Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Asia-Pacific Mucopolysaccharidosis Treatment Market Share by Region (2018-2029)

Figure 31. China Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Japan Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. South Korea Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Southeast Asia Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. India Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Australia Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Latin America Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Latin America Mucopolysaccharidosis Treatment Market Share by Country (2018-2029)

Figure 39. Mexico Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Brazil Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Middle East & Africa Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Middle East & Africa Mucopolysaccharidosis Treatment Market Share by Country (2018-2029)

Figure 43. Turkey Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Saudi Arabia Mucopolysaccharidosis Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 46. Denali Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 47. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 48. REGENXBIO Inc. Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 49. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 50. BioMarin Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 51. Lysogene Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 52. Abeona Therapeutics Inc. Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 53. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 54. Genzyme Corporation Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2018-2023)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

I would like to order

Product name: Global Mucopolysaccharidosis Treatment Market Research Report 2023

Product link: <https://marketpublishers.com/r/G3D55902CF86EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3D55902CF86EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970